Magne Henriksen

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)

Inger Camilla Solberg, I. Lygren, Jørgen Jahnsen et al. · Scandinavian Journal of Gastroenterology · 2008 · 728 citations

Medicine, Internal Medicine, Clinical Epidemiology +9

C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study

Magne Henriksen, Jørgen Jahnsen, I. Lygren et al. · Gut · 2008 · 418 citations

Medicine, Clinical Sciences, Internal Medicine +11

Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (the IBSEN study)

Magne Henriksen, I. Lygren, Jostein Sauar et al. · Inflammatory Bowel Diseases · 2006 · 271 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +8

Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study

Marte Lie Høivik, Bjørn Moum, Inger Camilla Solberg et al. · Gut · 2012 · 265 citations

Nursing, Chronic Disease Prevention, Occupational Health +15